Detected ·
Delix Therapeutics
$100MSeries C
Delix Therapeutics closed a $100M Series C, co-led by SV Health Investors' Dementia Discovery Fund (DDF) and Johnson & Johnson Innovation JJDC Inc., to advance Zalsupindole into Phase 2 trials and expand its neuroplastogen pipeline.
- Website
- www.delixtherapeutics.com
- linkedin.com/company/76400524
- Amount
- $100 000 000 USD
- Stage
- Series C
- Event
- Funding round
- Detected
- 2026-11-09 20:08:43 UTC
- Signal ID
- 13e40e39-0d32-4fee-be33-3dfd25bdc96a
As the API returns it
{
"id": "13e40e39-0d32-4fee-be33-3dfd25bdc96a",
"created_at": "2026-11-09T20:08:43.130138Z",
"company_name": "Delix Therapeutics",
"company_website_url": "www.delixtherapeutics.com",
"company_linkedin_url": "https://www.linkedin.com/company/76400524",
"event_type": "funding",
"funding_amount": 100000000,
"funding_currency": "USD",
"funding_stage": "series_c",
"message": "*Delix Therapeutics closed a $100M Series C, co-led by SV Health Investors' Dementia Discovery Fund (DDF) and Johnson & Johnson Innovation JJDC Inc., to advance Zalsupindole into Phase 2 trials and expand its neuroplastogen pipeline.*"
}